Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimizing second-line therapy for chronic myeloid leukemia.

Indian journal of cancer - 1 Jan 2000

Raja T

Abstract excerpt

Treatment of chronic myeloid leukemia has evolved from symptom control to long-term disease-free survival with cure potentially round the corner. This required faster, deeper, and longer response. Optimizing treatment decisions therefore requires clear understanding of and strict implementation of guidelines for shift from imatinib. In patients who are resistant to or intolerant of imatinib, second-line TKIs have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Dasatinib
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Share to Pyrimidines

Share to Thiazoles

Source

Identifiers

PMID: 22842168
DOI: 10.4103/0019-509X.98918

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimizing second-line therapy for chronic myeloid leukemia.PMID 22842168Read ↗

Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.Semantic proximity Read ↗

Clinical roundtable monograph: Unmet needs in the management of chronic myelogenous leukemia.Semantic proximity Read ↗

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.Semantic proximity Read ↗

Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia.Semantic proximity Read ↗

Second line small molecule therapy options for treating chronic myeloid leukemia.Semantic proximity Read ↗

A review of the European LeukemiaNet recommendations for the management of CML.Semantic proximity Read ↗

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations.Semantic proximity Read ↗

Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and managementSemantic proximity Read ↗

Third-generation tyrosine kinase inhibitors and beyond.Semantic proximity Read ↗

Tyrosine kinase inhibitors: the first decade.Semantic proximity Read ↗

New directions in the treatment of imatinib failure and/or resistance.Semantic proximity Read ↗

[Key points in second-line therapy for chronic myeloid leukemia].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.